Individual variation in genes encoding drug-metabolizing enzymes and transporters can significantly influence the safety and efficacy of antifungal therapies. Our MycoMap – PGx panel focuses on clinically relevant gene-drug interactions for key antifungals:

Key Features:

• Genotyping of polymorphisms in genes like CYP2C19, CYP3A4, CYP3A5, ABCB1 etc.
• Tailored recommendations for antifungal agents such as voriconazole, posaconazole, and fluconazole
• Identification of ultra-rapid, rapid, intermediate or poor metabolizers
• Dose adjustment and toxicity risk assessment

Clinical Utility

• Supports decision-making in patients with invasive aspergillosis, candidiasis, or undergoing stem cell/bone marrow transplantation
• Reduces risk of drug toxicity and therapeutic failure
• Enables precision antifungal therapy for optimal outcomes

All reports are interpreted by experts and include evidence-based recommendations aligned with CPIC and other international guidelines.